Shares of EyePoint Pharmaceuticals dropped nearly 30% premarket on Monday after the company said its experimental eye disease treatment failed to meet a clinical trial’s main goal.
Source: https://www.marketwatch.com/story/eyepo ... topstories
EyePoint Pharmaceuticals’ stock plunges as eye treatment fails to meet trial goal
